Fennec Pharmaceut…
USUSDFennec Pharmaceuticals Inc (TO:FRX) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- fennecpharma.com
- Investor Relations
- investors.fennecpharma.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- RESEARCH TRIANGLE PARK, United States
- Management
- Jeffrey S. Hackman
- Neueste Berichte
- Mitarbeiter
- 35
- Börsennotiert Seit
- 12.06.2001 (TO:FRX)
- Ausstehende Aktien
- 35.07 Mio. Stand 2026-08-11
- Streubesitz
- 19.88 Mio.
- Marktkapitalisierung
- 375.57 Mio. USD
- Insider
- 14.13%
- Institutionelle Anleger
- 54.24%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- Verlust
- P/B
- 8.97
- FCF
- 3.92 Mio. USD
- Schulden
- 19.4 Mio. USDNettoliquidität
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- Nettogewinn
- NAV
Beschreibung
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Rosalind Advisors, Inc. | 9.07% | 3.19 Mio. | 2026-06-30 |
| AIGH Capital Management… | 7.07% | 2.49 Mio. | 2026-06-30 |
| Solas Capital Management… | 5.38% | 1.89 Mio. | 2026-06-30 |
| Blackrock Inc. | 4.92% | 1.73 Mio. | 2026-06-30 |
| AWM Investment Company,… | 3.3% | 1.16 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 2.39% | 839 306 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.32% | 815 192 | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.11% | 742 194 | 2026-08-31 |
| Prospect Capital Advisor… | 1.42% | 497 800 | 2026-06-30 |
| State Street Corporation | 1.21% | 426 004 | 2026-06-30 |
| Geode Capital Management… | 1.15% | 402 566 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.9% | 316 471 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.78% | 274 781 | 2026-08-31 |
| ANDRADE ROBERT C (Chief… | ≈0.69% | 241 306 | 2026-08-31 |
| Jane Street Group, LLC | 0.67% | 233 877 | 2026-06-30 |
| VANGUARD SCOTTSDALE FUND… | 0.42% | 149 156 | 2026-05-31 |
| RAYKOV ROSTISLAV CHRISTO… | ≈0.35% | 124 411 | 2026-09-01 |
| Bridgeway Funds, Inc.-Ul… | 0.31% | 108 005 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.28% | 98 294 | 2026-08-31 |
| College Retirement Equit… | 0.24% | 85 124 | 2026-06-30 |
| SCHWAB CAPITAL TRUST-Sch… | 0.2% | 70 504 | 2026-07-31 |
| HACKMAN JEFFREY S (Chief… | ≈0.19% | 67 461 | 2026-09-30 |
| RALLIS CHRISTOPHER ANIGE… | ≈0.18% | 63 077 | 2026-05-11 |
| Quantitative Master Seri… | 0.14% | 50 481 | 2026-06-30 |
| CIOFFI CHRISTIANA MARIE… | ≈0.07% | 24 644 | 2026-08-31 |
| EVANS TERRY L (Officer) | ≈0.06% | 21 687 | 2026-09-30 |
| SAYAD PIERRE SARGIS PH.D… | ≈0.03% | 9 687 | 2026-09-30 |
| BRUGHERA MARCO MARIA (Di… | — | 0 | 2026-09-15 |
| SOUTHPOINT CAPITAL ADVIS… | — | — | 2025-12-24 |
Mit Google Anmelden